Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  dovitinib lactate
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-9 of 9 for your search:
Start Over
Dovitinib Plus Docetaxel in Gastric Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 74
Sponsor: Other
Protocol IDs: AMC1302, NCT01921673
TKI258 for Metastatic Inflammatory Breast Cancer Patients
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2010-0296, NCI-2011-00299, NCT01262027
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CTKI258A2210, 2011-001230-42, NCT01528345
Dovitinib for Gastric Cancer With FGFR2 Amplification
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AMC1202, NCT01719549
Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: KCSG-GU11-05, GU11-05, NCT01741116
Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 20 and over
Sponsor: Other
Protocol IDs: 2012-09-070-002, NCT01861197
Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CTKI258ADE02T, NCT01972750
Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 19 and over
Sponsor: Other
Protocol IDs: AMC1401, NCT02268435
Start Over